TrialSignal
Clinical trial intelligence report
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03400033
Status
COMPLETED
Phase
Phase 3
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
The ASCEND-TD trial evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against the standard of care, epoetin alfa, in hemodialysis patients with anemia. The study aimed to demonstrate daprodustat's efficacy and safety in maintaining hemoglobin levels.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03400033
Indication
Anaemia
Modality
small molecule
Target
Anemia in Chronic Kidney Disease (CKD)
Intervention
Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.